HRP20192266T1 - Kompozicije i postupci za nekirurško liječenje ptoze - Google Patents

Kompozicije i postupci za nekirurško liječenje ptoze Download PDF

Info

Publication number
HRP20192266T1
HRP20192266T1 HRP20192266TT HRP20192266T HRP20192266T1 HR P20192266 T1 HRP20192266 T1 HR P20192266T1 HR P20192266T T HRP20192266T T HR P20192266TT HR P20192266 T HRP20192266 T HR P20192266T HR P20192266 T1 HRP20192266 T1 HR P20192266T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
oxymetazoline
phenylephrine
use according
Prior art date
Application number
HRP20192266TT
Other languages
English (en)
Croatian (hr)
Inventor
Mark Silverberg M.D.
Original Assignee
Voom, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voom, Llc filed Critical Voom, Llc
Publication of HRP20192266T1 publication Critical patent/HRP20192266T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D47/00—Closures with filling and discharging, or with discharging, devices
    • B65D47/04—Closures with discharging devices other than pumps
    • B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
    • B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HRP20192266TT 2011-03-03 2012-02-24 Kompozicije i postupci za nekirurško liječenje ptoze HRP20192266T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161448949P 2011-03-03 2011-03-03
US13/218,584 US20120225918A1 (en) 2011-03-03 2011-08-26 Compositions and Methods for Non-Surgical Treatment of Ptosis
US13/270,577 US8357714B2 (en) 2011-03-03 2011-10-11 Compositions and methods for non-surgical treatment of ptosis
PCT/US2012/026496 WO2012118704A1 (en) 2011-03-03 2012-02-24 Compositions and methods for non-surgical treatment of ptosis
EP12709421.7A EP2680829B1 (en) 2011-03-03 2012-02-24 Compositions and methods for non-surgical treatment of ptosis

Publications (1)

Publication Number Publication Date
HRP20192266T1 true HRP20192266T1 (hr) 2020-03-20

Family

ID=46753678

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192266TT HRP20192266T1 (hr) 2011-03-03 2012-02-24 Kompozicije i postupci za nekirurško liječenje ptoze

Country Status (24)

Country Link
US (8) US20120225918A1 (https=)
EP (2) EP3653205A3 (https=)
JP (1) JP6106100B2 (https=)
KR (1) KR101889392B1 (https=)
CN (1) CN103501771B (https=)
AU (1) AU2012223615B2 (https=)
BR (1) BR112013022094A2 (https=)
CA (1) CA2827285C (https=)
CY (1) CY1122565T1 (https=)
DK (1) DK2680829T3 (https=)
ES (1) ES2750123T3 (https=)
HR (1) HRP20192266T1 (https=)
HU (1) HUE046740T2 (https=)
LT (1) LT2680829T (https=)
MX (1) MX345042B (https=)
PL (1) PL2680829T3 (https=)
PT (1) PT2680829T (https=)
RS (1) RS59636B1 (https=)
RU (1) RU2582392C2 (https=)
SG (1) SG192801A1 (https=)
SI (1) SI2680829T1 (https=)
SM (1) SMT201900718T1 (https=)
WO (1) WO2012118704A1 (https=)
ZA (1) ZA201307262B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
UA113525C2 (xx) 2011-09-20 2017-02-10 Спосіб лікування пресбіопії
CA2911472A1 (en) * 2013-05-06 2014-11-13 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
CA2869060A1 (en) * 2014-07-28 2016-01-28 Queen's University At Kingston Dosage forms and methods for diagnosing sympathetic nervous system dysfunction
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CN108883308A (zh) * 2016-01-26 2018-11-23 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
CN106726115B (zh) * 2016-12-22 2023-01-20 上海交通大学医学院附属第九人民医院 一种眼睑功能矫正器
CN106938039A (zh) * 2017-03-29 2017-07-11 卢仁华 眼睑下垂的治疗药物
US20190321334A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
CN108635434A (zh) * 2018-06-24 2018-10-12 吴安相 一种治疗眼睑下垂的侗族中药配方
SG11202104410SA (en) * 2018-11-26 2021-06-29 Cellix Bio Private Ltd Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
WO2021216909A1 (en) * 2020-04-23 2021-10-28 Okogen, Inc. Treatment of viral conjunctivitis
WO2022187306A1 (en) 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1117588B (de) 1960-09-30 1961-11-23 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates
US3670087A (en) * 1970-10-16 1972-06-13 Miles Lab Method of lowering intraocular pressure
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
DE3227741A1 (de) 1982-07-24 1984-01-26 Hoechst Ag, 6230 Frankfurt 1-phenyl-isochinolinderivate und verfahren zu ihrer herstellung
FR2549015B1 (fr) * 1983-07-13 1986-06-13 Oreal Ensemble compte-gouttes
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
AU7081598A (en) * 1997-04-24 1998-11-13 Taisho Pharmaceutical Co., Ltd. Eye drops
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US5885550A (en) * 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
EP1328214A4 (en) * 2000-09-20 2009-07-29 Shahinian Lee Jr NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
EP1326642A2 (en) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
US7780976B2 (en) * 2002-05-30 2010-08-24 Eye Care And Cure, Asia Apparatus and method for delivering controlled quantities of one or more agents to the eye
RU2005101331A (ru) * 2002-06-20 2006-01-20 Новартис Консьюмер Хелс С.А. (Ch) Назальная композиция, включающая мукополисахарид и пропиленгликоль
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US7022740B2 (en) 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
JP4942328B2 (ja) * 2004-11-01 2012-05-30 ロート製薬株式会社 ビタミンｂ６類含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP4956981B2 (ja) * 2005-01-05 2012-06-20 大正製薬株式会社 オキシメタゾリン含有水性組成物
AU2007227091B2 (en) 2006-03-17 2013-02-07 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
WO2008070185A2 (en) 2006-12-06 2008-06-12 The Trustees Of Columbia University In The City Of New York Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
WO2009061431A2 (en) * 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
EP2408453B1 (en) * 2009-03-17 2022-01-05 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
WO2010141831A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
CN103140217B (zh) 2010-08-06 2015-08-19 盖尔德马研究及发展公司 用于治疗或预防皮肤病的化合物的组合
US8883838B2 (en) 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
JP6225030B2 (ja) * 2011-02-15 2017-11-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 酒さの症状を治療するためのオキシメタゾリンの薬学的クリーム組成物
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
JP2015518006A (ja) 2012-05-25 2015-06-25 エクスクリア インコーポレイテッド キシリトール系の抗粘膜組成物及び関連する方法並びに組成物
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
AU2015274532B2 (en) 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CN108883308A (zh) 2016-01-26 2018-11-23 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Also Published As

Publication number Publication date
RU2013142602A (ru) 2015-04-10
US9867808B2 (en) 2018-01-16
US20180338953A1 (en) 2018-11-29
US10912765B2 (en) 2021-02-09
AU2012223615A1 (en) 2013-10-24
CY1122565T1 (el) 2021-01-27
US20220218669A1 (en) 2022-07-14
LT2680829T (lt) 2019-12-27
ES2750123T3 (es) 2020-03-25
SMT201900718T1 (it) 2020-01-14
WO2012118704A1 (en) 2012-09-07
US20200009114A1 (en) 2020-01-09
PT2680829T (pt) 2019-12-10
MX345042B (es) 2017-01-16
US20160038465A1 (en) 2016-02-11
US20120225919A1 (en) 2012-09-06
ZA201307262B (en) 2015-02-25
SI2680829T1 (sl) 2020-02-28
US20200360345A1 (en) 2020-11-19
CN103501771A (zh) 2014-01-08
DK2680829T3 (da) 2019-11-18
RS59636B1 (sr) 2020-01-31
CN103501771B (zh) 2016-05-11
RU2582392C2 (ru) 2016-04-27
EP2680829A1 (en) 2014-01-08
US8357714B2 (en) 2013-01-22
MX2013009597A (es) 2014-01-08
EP3653205A3 (en) 2020-08-26
KR20140013013A (ko) 2014-02-04
EP3653205A2 (en) 2020-05-20
US20120225918A1 (en) 2012-09-06
JP2014506927A (ja) 2014-03-20
US20120225920A1 (en) 2012-09-06
US9018240B2 (en) 2015-04-28
CA2827285C (en) 2019-05-07
JP6106100B2 (ja) 2017-03-29
BR112013022094A2 (pt) 2017-06-27
CA2827285A1 (en) 2012-09-07
SG192801A1 (en) 2013-09-30
PL2680829T3 (pl) 2020-03-31
HUE046740T2 (hu) 2020-03-30
KR101889392B1 (ko) 2018-08-17
EP2680829B1 (en) 2019-09-25
NZ614719A (en) 2015-05-29
AU2012223615B2 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
HRP20192266T1 (hr) Kompozicije i postupci za nekirurško liječenje ptoze
JP2014506927A5 (https=)
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
JP2012036176A5 (https=)
JP2014501281A5 (https=)
PH12013501579A1 (en) Androgen composition for treating an opthalmic condition
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
EP2528602A4 (en) FORMULAS FROM BENDAMUSTIN
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX2015002300A (es) Nanoparticulas polimericas de finasterida y minoxidil, metodo para preparar las mismas, suspension acuosa que contiene las mismas, composicion farmaceutica y su uso.
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
UA113756C2 (xx) Топічні композиції, що містять фіпроніл і перметрин, та способи їх застосування
HK1208441A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
HK1222337A1 (zh) 用於施加药物活性成分或化妆品活性成分的局部组合物和载体
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
WO2013046059A3 (en) Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose
JP6449774B2 (ja) 両性イオン性ソフトコンタクトレンズ用眼科用組成物
WO2015077148A3 (en) Method of treating ocular disorders
BR112017014379A2 (pt) composição para o tratamento de infecções causadas pelo acaro demodex spp
FR2976808B1 (fr) Composition filmogene et son utilisation pour le traitement de l'herpes
HK1215197A1 (zh) 凝胶组合物
CA2797347A1 (en) Methods and compositions for treating dry eye
GR1007906B (el) Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
WO2015041192A1 (ja) 陰イオン性ソフトコンタクトレンズ用眼科用組成物
JP6401699B2 (ja) 両性イオン性ソフトコンタクトレンズ用眼科用組成物